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Prospective studies have found that the risk of breast
cancer rises with increases in endogenous oestradiol le-
vels. Recently published data from the placebo group of
the multiple outcomes of raloxifene evaluation (MORE)
trial showed that the postmenopausal osteoporotic wo-
men with highest circulating levels of oestradiol within a
menopausal range had the greatest risk of developing
breast cancer through four years. Additionally the
greatest reduction in breast cancer in the raloxifene-
treated group was seen in the highest risk group,
whereas the lowest risk group had no reduction. If
conﬁrmed by future studies, sensitive measurements of
oestradiol levels, at least in postmenopausal women,
may be an appropriate way to assess breast cancer risk
for those patients considering chemoprevention.
In the United States, breast cancer is the second most
common cancer in women, only recently surpassed by
lung cancer There are more 180 000 new cases diagnosed
annually andmore than 45 000 deaths. The emotional and
psychological ramiﬁcations of developing breast cancer
and the concomitant fear of the disease is overwhelming
for many women. Tamoxifen, long used to treat women
with breast cancer, is now approved by the FDA for
breast cancer risk reduction in women at high-risk. This
was based on data supplied from the national surgical
adjuvant breast and bowel project (NSABP)-P1 Trial
(BCPT) [1]. Raloxifene, a benzothiophene selective oes-
trogen receptor modulator (SERM), signiﬁcantly lowers
new onset invasive breast cancer in osteoporotic women
through 4 years of exposure [2]. Currently, study of ta-
moxifen and raloxifene (STAR) is ongoing, but it appears
likely that, ultimately, raloxifene too, will be approved for
chemoprevention of breast cancer. Thus, the assessment
of breast cancer risk is important and will only become
more so in the future in order to decide which women are
appropriate candidates for such chemoprevention.
In the past, isolated risk factors for breast cancer
have been assigned a Relative Risk or Odds Ratio.
Such factors with varying Relative Risks include early
menarche, late menopause, obesity, alcohol use, hor-
mone-replacement therapy (HRT), ﬁrst-degree relative
with breast cancer, ﬁrst live birth after age 35 years, as
well as any gene mutations (BRCA-1 or BRCA-2) or
pre-invasive breast lesions. Relative Risks or Odds
Ratio of the speciﬁc characteristic gives the likelihood
of a group of women with that characteristic devel-
oping breast cancer compared with a group of women
without that characteristic. This is of limited value to
an individual woman. Developing models that estimate
absolute risk of developing breast cancer taking into
consideration various risk factors, seems to be a better
way to counsel patients. One such model was devel-
oped by Gail [3]. Based on 2852 detected cancers (10%
in situ), and 3146 controls between 1973 and 1980 at
28 centres as part of the Breast Cancer Detection
Demonstration Project (BCDDP), a model to predict
an individual woman’s risk of developing breast cancer
in the next 5 years and within her lifetime was devel-
oped. Oral contraceptives, methyl xanthenes and ci-
garette smoking had no relationship with the
development of breast cancer. Alcohol, long-term
HRT use and height caused an increased risk, but the
number of women with these risk factors was limited,
so these variables were ultimately not included. The
model was later modiﬁed for invasive breast cancer
only and incorporated data from SEER (Surveillance,
Epidemiology, and End Results) to include non-Cau-
casian women. This ﬁnal version gives a risk based on
age, age at menarche, age at ﬁrst live born (if any),
number of ﬁrst-degree relative with breast cancer,
number of previous breast cancer biopsies, and if any
were hyperplastic.
Rockhill and colleagues [4] applied the Gail model to
almost 100 000 women in the Nurses Health Study be-
tween 1992 and 1997. E/O (expected to observed) ratios
EJC Supplements Vol 2 No. 9 (2004) 26–28
www.ejconline.com
EJC
Supplements
* Tel.: +1 2122637416; fax: +1 2122636259.
E-mail address: steven.goldstein@med.nyu.edu.
1359-6349/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejcsup.2004.08.006
were close to 1. Thus, the model was accurate in pre-
dicting risk in a population. However the discriminatory
accuracy for an individual was only 0.58. When a 5 year
cut-oﬀ point of 1.66% risk of developing breast cancer
(the level used in the BCPT) was used to deﬁne ‘‘high-
risk’’, only 44% of 13 054 women who developed breast
cancer had a score >1.67%. In other words, most of the
women who developed breast cancer had a 5 year risk
<1.67%. Another shortcoming of the Gail model is that
of ‘‘breast biopsies’’. In the original description, there
was no mention of what is a ‘‘breast biopsy’’. This data
was derived between 24 and 33 years ago. Today, nu-
merous less invasive techniques for breast tissue sam-
pling have emerged, including ﬁne-needle aspiration,
core biopsy, and stereotactical mammographic-guided
biopsy. Ultrasound-guided biopsy and, most recently, in
1993, the introduction of the Mammotome biopsy
system (Biopsys Medical Instruments, San Juan Capis-
trano, California). Thus, the number of ‘‘biopsies’’ wo-
men are undergoing is increasing dramatically and this
has a tremendous eﬀect on an individual’s assessment of
risk by the Gail model. For instance, a hypothetical 50-
year Caucasian woman who is nulliparous with me-
narche at age 11 years and no ﬁrst-degree relative with
breast cancer and no previous breast biopsies yields a
Gail score of 1.2% risk over the next 5 years i.e. low-risk.
If the same woman had 3 previous breast ‘‘biopsies’’
none of which were hyperplasic her Gail score rises to
1.8% making her a candidate for chemoprevention.
Other shortcomings of the Gail model include that it
is not appropriate for risk assessment in women less
than 35 years of age, women with a history suggestive of
hereditary breast cancer, a personal history of earlier
breast cancer, lobular carcinoma in situ (LCIS) or ductal
carcinoma in situ (DCIS), and women not undergoing
annual screening.
Ultimately, assessment of risk based on an in-
dividual’s own ﬁndings rather than population-based
characteristics would be desirable. Examples might in-
clude things like a patient’s breast density on imaging
study or ultra-sensitive measurements of her circulating
endogenous hormones, such as oestradiol, oestrone, and
even testosterone.
Harvey and colleagues [5] published a meta-analysis
of 12 studies. Breast density was quantitated by visual
assessment or planimetry. Increased mamographic
density is an independent risk factor for breast cancer
with Odds Ratios ranging from 1.8–6.0 (average 4.0).
Possible explanations for the association of increased
density and risk of breast cancer include development
of premalignant lesions, elevated growth factors,
overactive aromatase causing increased oestrogen
within the breast and possibly even a hereditary basis
for breast density. Furthermore, density is hormon-
ally-responsive and is inﬂuenced by alcohol intake and
diet.
Prospective studies have found that the risk of breast
cancer rises with an increase in endogenous oestrogens.
Toniolo and colleagues [6] was the ﬁrst to conﬁrm the
link between circulating oestrogens in breast cancer risk
in a large prospective epidemiological study. Of 130
cancers in 260 matched controls through 5 1/2 years of
study on stored serum specimens, women with higher
levels of oestrone, and total and free oestradiol had a
higher rate of breast cancer.
Cauley and colleagues [7] published a prospective
case-cohort study from 4 centres for an average of 3.2
years involving 97 women with cancer and 244 controls.
Women with the highest concentration of bioavailable
oestradiol had a RR = 3.6 (95% CI, 1.3–10.0). In ad-
dition, the concentration of free testosterone had a RR
= 3.3 (95% CI, 1.1–10.3).
Recently published data from the multiple out-
comes of raloxifene evaluation (MORE) trial [8] may
oﬀer promise of a type of risk assessment that can be
expected for the future. This was an osteoporosis
treatment trial. All patients were postmenopausal i.e.
serum oestradiol < 20 pmol/l. However, using an ul-
trasensitive assay for oestradiol, they were able to
stratify these patient’s quantitative oestradiol levels. In
the placebo group the Relative Risk of developing
invasive breast cancer for undetectable levels, levels
between 0 and 5 pmol/l, between 5–10 and 10–20
pmol/l was 0.6, 1.2, 1.8 and 3.0, respectively. In other
words, the postmenopausal women with the highest
circulating levels of oestradiol within a menopausal
range had the greatest risk. Additionally, the greatest
reduction in breast cancer in the raloxifene group was
seen in the highest risk group, whereas the lowest risk
group had no reduction.
In summary, the assessment of breast cancer risk is
important and will only become more so in the future.
Methods to determine an individual woman’s risk of
developing breast cancer will be important to assess
those patients who are considering chemoprevention.
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